Skip to main content
. 2020 Jun 27;24:100420. doi: 10.1016/j.eclinm.2020.100420

Table 5.

Summary of sensitivity analysis results relative to FMT- NGT.

Treatment option Expected Value Difference ICER
Costs £ QALYs Cost £ QALYs £/ QALYs
Scenario 1: Similar efficacy for FMT colonoscopy and NGT
FMT – NGT 8406 0.663
FMT – Colonoscopy 11,716 0.657 3311 −0.007 Dominated
Fidaxomicin 14,399 0.577 5993 −0.086 Dominated
Vancomycin 17,279 0.513 8873 −0.151 Dominated
Scenario 2: Recurrence rate=0.2 for all treatment options
FMT – NGT 10,706 0.615
FMT – Colonoscopy 14,779 0.600 4073 −0.015 Dominated
Fidaxomicin 15,389 0.561 4683 −0.053 Dominated
Vancomycin 16,635 0.520 5929 −0.094 Dominated
Scenario 3: constant efficacy for FMT options for the 1st and 2nd dose
FMT – NGT 8281 0.671
FMT – Colonoscopy 11,402 0.670 3121 −0.001 Dominated
Fidaxomicin 14,395 0.577 6117 −0.094 Dominated
Vancomycin 17,279 0.513 8998 −0.159 Dominated
Scenario 4: 10 days hospital stay for FMT
FMT – NGT 11,786 0.645
Fidaxomicin 14,399 0.577 2612 −0.068 Dominated
FMT – Colonoscopy 14,585 0.657 2799 +0.012 239,063
Vancomycin 17,279 0.513 5493 −0.132 Dominated
Scenario 5: 6 weeks hospital stay for vancomycin TP
FMT – NGT 23,498 0.645
FMT – Colonoscopy 25,404 0.657 1906 +0.012 162,801
Fidaxomicin 41,325 0.577 17,827 −0.068 Dominated
Vancomycin 46,564 0.513 23,066 −0.132 Dominated
Scenario 6: CDI related Mortality for FMT = 12%
FMT – NGT 9034 0.653
FMT – colonoscopy 11,843 0.662 2809 +0.009 301,022
Fidaxomicin 14,399 0.577 5364 −0.076 Dominated
Vancomycin 17,279 0.513 8245 −0.140 Dominated

Abbreviations: ICER, Incremental cost effectiveness ratio; QALYs, Quality Adjusted Life Years; FMT, Faecal Microbiota Tube; NGT, Nasogastric Tube.